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VaccineLPs) were produced in insect cells using a recombinant baculovirus expression
system and their efﬁcacy for protection against Ebola virus infection was investigated. Two immunizations
with 50 μg Ebola VLPs (high dose) induced a high level of antibodies against Ebola GP that exhibited strong
neutralizing activity against GP-mediated virus infection and conferred complete protection of vaccinated
mice against lethal challenge by a high dose of mouse-adapted Ebola virus. In contrast, two immunizations
with 10 μg Ebola VLPs (low dose) induced 5-fold lower levels of antibodies against GP and these mice were
not protected against lethal Ebola virus challenge, similar to control mice that were immunized with 50 μg
SIV Gag VLPs. However, the antibody responses against GP were boosted signiﬁcantly after a third
immunization with 10 μg Ebola VLPs to similar levels as those induced by two immunizations with 50 μg
Ebola VLPs, and vaccinated mice were also effectively protected against lethal Ebola virus challenge.
Furthermore, serum viremia levels in protected mice were either below the level of detection or signiﬁcantly
lower compared to the viremia levels in control mice. These results show that effective protection can be
achieved by immunization with Ebola VLPs produced in insect cells, which give high production yields, and
lend further support to their development as an effective vaccine strategy against Ebola virus.
© 2008 Elsevier Inc. All rights reserved.Introduction
Ebola virus, along with Marburg virus, belongs to the Filoviridae
family and causes severe viral hemorrhagic fevers with a high fatality
rate up to 90%, for which there is no effective treatment or licensed
vaccine at present. Since its ﬁrst identiﬁcation in the 1977 outbreak in
Africa, Ebola virus outbreaks have caused over 1800 human infections
with over 1300 deaths and such outbreaks have become increasingly
frequent in recent years (Groseth et al., 2007). Recent studies indicate
that African fruit bats may be natural reservoirs for both Ebola and
Marburg viruses (Leroy et al., 2005; Towner et al., 2007), suggesting
that these viruses will remain endemic in these regions and outbreakst Department of Microbiology
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y.
l rights reserved.will continue to occur through zoonotic transmission. Outbreaks in
humans are likely to stem from contact with infected animals followed
by spread among humans through close person-to-person contacts.
Ebola viruses cause acute infection in humans with an incubation
period usually between 4–10 days, that typically starts with headache,
chill, myalgia, as well as other signs of infection, followed by more
severe symptoms including weight loss, delirium, shock, massive
hemorrhaging, and multi-organ dysfunction that eventually lead to
death in about two to three weeks (Bwaka et al., 2007; Peters and
DeLuc, 1999). Although outbreaks of Ebola virus have largely been
conﬁned to endemic regions, their high fatality rate, ability to transmit
person-to-person, and low lethal infectious dose make Ebola virus a
dangerous threat to public health and pose a great risk for researchers
working with these viruses as well as health care personnel treating
patients during outbreaks. Furthermore, their potential to be devel-
oped into aerosolized biological weapons also causes grave concern
for their use as a bioterrorism agent (Bray, 2003). These features
together with the lack of effective treatment underscore the need to
develop an efﬁcacious vaccine strategy against Ebola virus infection.
While there is no licensed vaccine, signiﬁcant progress has been
made and results from recent studies demonstrate that viral hemor-
13Y. Sun et al. / Virology 383 (2009) 12–21rhagic fevers caused by Ebola virus infection can be successfully
controlled in animals, including non-human primates, by effective
vaccinations (Hart, 2003). Highly promising results have been
obtained with viral-vector-based vaccine approaches. The ﬁrst
vaccine strategy that was shown to successfully protect non-
human primates against Ebola virus infection employed an immu-
nization regimen of DNA vaccine priming followed by recombinant
adenovirus vaccine boosting (Sullivan et al., 2000). Subsequent
studies showed that a single immunization with recombinant
adenoviruses expressing the Ebola GP and NP proteins or the GPFig. 1. (A) Determining the amount of GP protein in Ebola VLPs by a quantitative ELISA. Eb
detected by ELISA using a monoclonal antibody against GP. A standard curve was construct
known concentrations, and the amount of GP proteins in Ebola VLP preparations was calcula
(ng/μg). (B) Western blot analysis of Ebola VLP preparations. Ebola VLPs were produced by co
the MOI of 5 and 2 respectively, and puriﬁed as described in Materials and methods. The VLP
preparations were mixed with reducing protein sample buffer, heated at 95 °C for 5 min,
antibodies against Ebola VP40 or GP proteins as indicated. Lanes 1, control SIV Gag VLPs; lan
staining of VLP preparations. Lanes 1, control SIV Gag VLPs; lanes 2, Ebola VLPs (preparatio
preparations were stained with 1% uranyl acetate followed by examination under a Hitachialone was sufﬁcient to confer complete protection against EBOV
infection in non-human primates (Sullivan et al., 2003; 2006). More
recently, recombinant VSV and recombinant human PIV3 virus based
vaccines that express Ebola virus GP were also developed and shown
to confer complete protection of non-human primates against Ebola
virus infection (Jones et al., 2005; Bukreyev et al., 2007). However,
the pre-existing immune response against the adenovirus viral
vector may potentially reduce the efﬁcacy of recombinant adeno-
virus replicon-based vaccines in human applications. Also, the
recombinant VSV and PIV3 viral-vector-based vaccines are replica-ola VLPs were coated onto a microtiter plate and the level of GP proteins in VLPs was
ed by coating the plate with serial dilutions of puriﬁed Ebola GP1-histag protein with
ted and expressed as nanograms of GP protein per microgram of total proteins in VLPs
-infection of Sf9 insect cells with recombinant baculoviruses expressing GP and VP40 at
preparations were re-suspended in PBS at the concentration of 1 μg/μl and 5 μg of VLP
and then subjected to SDS-PAGE followed by Western blot analysis using monoclonal
es 2, Ebola VLPs (preparation 1); lanes 3, Ebola VLPs (preparation 2). (C) Coomassie blue
n 1); lanes 3, Ebola VLPs (preparation 2). (D) Negative staining of Ebola VLPs. The VLP
-H7500 transmission electron microscope.
14 Y. Sun et al. / Virology 383 (2009) 12–21tion competent and may raise safety concerns for use as a preventive
human vaccine.
These limitations of viral vector-based vaccines underscore the
need for developing alternative vaccine strategies that can meet both
safety and efﬁcacy criteria for prevention of Ebola virus infection. In
particular, expression of viral structural proteins leads to assembly
and release of particles from the cells, which are designated as virus-
like particles (VLPs) due to their resemblance to virions in size and
morphology (Johnson and Chiu, 2000). Like many viruses, expression
of ﬁlovirus structural proteins VP40 and GP leads to assembly and
release of VLPs that are similar to infectious virions in morphology
(Aman et al., 2003, Hartlieb and Weissenhorn, 2006). Expression of
VP40 alone leads to efﬁcient assembly and budding of VLPs from
mammalian 293T cells and co-expression of VP40 and GP proteins
results in release of VLPs containing both proteins (Bavari et al.,
2002, Noda et al., 2002). Further, co-expression of GP was found to
signiﬁcantly enhance the release of VP40 proteins in the form of
VLPs, indicating that it may interact with VP40 and facilitate VLP
assembly and release from cells (Bavari et al., 2002, Licata et al.,
2004). Of particular interest, recent studies on Ebola virus-like
particles (VLPs) demonstrated their potential as an effective vaccine
strategy against Ebola infection. It has been shown that three
immunizations with Ebola VLPs produced in mammalian 293T cells
successfully protected mice against lethal challenge by mouse-
adapted Ebola virus (Warﬁeld et al., 2003). Furthermore, when given
in combination with an adjuvant, these VLPs were able to protect
against lethal Ebola virus challenge by a two-dose immunization
regimen in mice (Warﬁeld et al., 2005) and by a single-dose
immunization regimen in guinea pigs (Swenson et al., 2005).
Moreover, it was recently reported that mammalian cell-produced
Ebola VLPs also effectively protected non-human primates against
lethal Ebola virus challenge when given in formulation with an
adjuvant (Warﬁeld et al., 2007a). These results show that Ebola VLPs
represent a promising alternative to viral vector-based vaccines for
protection against Ebola virus infection.
We have previously reported that Ebola VLPs produced in insect
cells exhibit dendritic cell stimulating activities similar to Ebola VLPs
produced in mammalian cells and can induce neutralizing antibodies
against Ebola GP-mediated virus infection (Ye et al., 2006). However, it
was also observed that Ebola virus GP proteins exhibit a smaller
molecular weight compared to those produced in mammalian cells,
possibly due to differences in glycosylation between mammalian and
insect cells (Mellquist-Reimenschneider et al., 2003). This raises the
question whether EBOV VLPs produced in insect cells are capable to
induce protective immune responses against Ebola virus infection, as
observed for those produced in mammalian cells. In this study, we
investigated the effect of dose and number of immunizations on
immune responses induced by immunization with Ebola VLPs
produced in insect cells, and evaluated their efﬁcacy to protect vacci-
nated mice against Ebola virus infection.Fig. 2. Schematic diagram of immunization and challenge study design. Four groups of mice (
as indicated. Mice of Groups 1, 2, and 3 were challenged by ip injection of 1000 pfu of mouse-
challenged at 10 weeks after the third immunization. Mice that survived the ﬁrst lethal chaResults
EBOV VLPs induce strong antibody responses
VLPs were produced by co-infection of Sf9 insect cells with recom-
binant baculoviruses expressing Ebola VP40 and GP proteins as
described previously (Ye et al., 2006). Because the EBOV GP is the
primary antigen for eliciting protective immune responses, we further
determined the levels of GP incorporation in EBOV VLP preparations
by a quantitative ELISA, using puriﬁed EBOV GP1-histag proteins as a
standard. As shown in Fig. 1A, the amount of GP proteins in EBOV VLPs
was similar between two separate preparations, at 23 and 19 ng/μg
respectively. Analysis by Western blot also detected similar levels of
EBOV GP and VP40 proteins in the two separate VLP preparations (Fig.
1B), indicating consistency for this production method. Further
characterization by Coomassie blue staining (Fig. 1C) revealed the
major band as VP40 with no visible GP in both VLP preparations,
similar as shown in our previous studies (Ye et al., 2006). VLPs were
also examined by negative staining under an electron microscope. As
shown in Fig. 1D, the VLP preparations were found to contain ﬁla-
mentous particles that are typical of Ebola virus as well as irregular
vesicles that may be broken particles or vesicles containing GP as
reported previously (Ye et al., 2006). After characterization, VLP
preparation 1, which contains a relatively higher level of GP, were used
in immunization studies as outlined in Fig. 2 to evaluate their
immunogenicity and protective efﬁcacy against EBOV infection.
We ﬁrst compared immune responses induced by immunization
with two different doses of Ebola VLPs. Mice (groups of 6) were
immunized twice at 4-week intervals with 10 μg or 50 μg Ebola VLPs
produced in Sf9 insect cells. In parallel, a control group was immu-
nized with 50 μg of SIV Gag VLPs that were similarly produced in SF9
insect cells. Blood samples were collected at 2 weeks after the second
immunization for analysis of antibody responses against the Ebola GP
antigen. As shown in Fig. 3A, analysis of antibody responses by ELISA
showed that two immunizations with 50 μg Ebola VLPs (EboVLP-50)
induced strong antibody responses against GP, which were more than
5-fold higher than the responses induced by two immunizations with
10 μg Ebola VLPs (EboVLP-10). No GP-speciﬁc antibody response was
detected in samples from the control group mice that were
immunized with SIV Gag VLPs. Also, Ebola VLP-induced antibodies
against GP were mainly of the IgG2a subtype along with signiﬁcant
levels of IgG2b antibodies but only minimal levels of IgG1 antibodies.
This was observed for both high and low-dose immunizations,
indicating that the dose of VLPs does not signiﬁcantly affect the pro-
ﬁle of induced antibody responses.
We further compared the neutralizing activity of antibody res-
ponses against Ebola GP-mediated virus entry induced by immu-
nization with different doses of VLPs using a pseudovirus-neutra-
lization assay. As shown in Fig. 3B, sera from high-dose Ebola VLP
immunizedmice (EboVLP-50) exhibited a neutralizing activity of aboutgroups of 6) were immunized with different doses of Ebola VLPs or control SIV Gag VLPs
adapted Ebola virus at 4 weeks after the second immunization andmice of Group 4 were
llenge (group 3) were challenged again 10 weeks later in parallel with mice in Group 4.
Fig. 3. Two immunizations with Ebola VLPs induce strong antibody responses against GP dose dependently. (A) Analysis of antibody responses by ELISA. Mice (groups of 6) were
immunized intramuscularly with different doses (10 or 50 μg) of Ebola VLPs or 50 μg SIV Gag VLPs twice at 4-week intervals. Serum samples were collected at two weeks after the
second immunization and assayed for Ebola GP-speciﬁc antibodies by ELISA using puriﬁed His-tagged GP1 as coating antigen. A standard curve was generated using puriﬁed mouse
antibodies for each mouse antibody subtype and used for calculation of the equivalent amount of GP-binding antibodies in serum samples. Control, mice immunized with control SIV
Gag VLPs; EboVLP-10, mice immunized with 10 μg Ebola VLPs; EboVLP-50, mice immunized with 50 μg Ebola VLPs. (B) Neutralization of Ebola GP pseudotyped HIV. Serum samples
collected after the second immunization were mixed with 500 pfu of Ebola GP-HIV pseudovirions at ﬁnal dilutions of 1:100, 1:300, and 1:900 as indicated. After incubation at 37 °C
for 1 h, the mixtures were added to JC53 cells seeded in a 96-well plate and incubated at 37 °C for 2 days. The level of β-galactosidase activity in each well was determined by
hydrolysis of the CPRG substrate bymeasuring the O.D. value at 590 nm as described in Materials and methods. A standard curvewas constructed by infecting JC53BL cells with serial
dilutions of Ebola GP-HIV pseudovirions and the neutralizing activity of serum samples is expressed as the percentage reduction of virus titers in sample wells compared to the titers
in control wells without mouse sera [(virus titer in control well−virus titer in sample well) /virus titer in control well×100%].
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1:300 dilution. On the other hand, sera from the low-dose Ebola VLP
immunized mice (EboVLP-10) exhibit a neutralizing activity of about
80% on average at 1:100 dilution, which dropped to below 60% at
1:300 dilution (signiﬁcantly lower compared to the EboVLP-50 group,
pb0.05). Moreover, sera from mice immunized with high-dose Ebola
VLPs retained neutralizing activities above 50% at 1:900 dilution with
sera from 4 of 6 mice exhibiting neutralizing activities above 80%,
whereas sera from mice immunized with low-dose Ebola VLPs
showed neutralizing activity below 50% at this dilution. As summar-
ized in Table 1, the 50% endpoint neutralizing titers (50%NT) in the
high-dose group are higher than those in the low-dose group, corre-
lating with the level of antibody responses. These results show that
strong neutralizing antibody responses against the Ebola GP were
induced by two immunizations with the higher dose of Ebola VLPs
produced in insect cells, correlating with the levels of GP-speciﬁc
antibody responses as determined be ELISA.Two immunizations with the high-dose Ebola VLPs protect mice against
lethal Ebola virus challenge
Encouraged by the high-level antibody responses induced by Ebola
VLPs, we challenged the immunizedmice after two immunizations. At
4 weeks after the second immunization, mice were challenged with
1000 pfu of mouse-adapted Ebola virus (approximately 30,000 LD50),
which was originally obtained by Bray et al. through passage in
suckling balb/c mouse and has been shown to be highly lethal for mice
by intra-peritoneal injection with an estimated 30 LD50 per pfu as
titered in Vero E6 cells (Bray et al., 1998). Mice were monitored daily
for signs of disease and weight changes after challenge and blood
samples were collected on day 4 after challenge for comparison of
viremia levels. Shown in Fig. 4 are the weight changes of mice after
challenge. Five of the six mice that were immunized with control SIV
Gag VLPs showed a rapid weight loss on day 4 post-challenge; one of
thesemice died on day 4 and the other four were sacriﬁced on day 5 in
Table 1
Viremia level, weight loss, and survival rate after lethal Ebola virus challenge (I)
Mouse Antibody level 50% NTa Viremia Weight loss Survival/
death
Control 1 ND ND 6.03×1010 N25% Died
2 ND ND 6.74×1010 N25% Died
3 ND ND 8.29×1010 N25% Died
4 ND ND 4.03×1010 N25% Died
5 ND ND 3.74×1010 N25% Died
6 ND ND ND 20% Survived
VLP-50-II 1 10822 ng/ml 1:900 ND NC Survived
2 13070 ng/ml 1:2700 ND NC Survived
3 22033 ng/ml 1:8100 ND NC Survived
4 16668 ng/ml 1:2700 ND NC Survived
5 16743 ng/ml 1:2700 ND NC Survived
6 9959 ng/ml 1:900 1.78×109 10% Survived
VLP-10-II 1 2832 ng/ml 1:300 4.21×1010 N25% Died
2 1972 ng/ml 1:100 9.17×1010 N25% Died
3 2052 ng/ml 1:100 5.33×1010 N25% Died
4 2027 ng/ml 1:300 3.31×1010 N25% Died
5 2432 ng/ml 1:300 1.64×1010 N25% Died
6 2797 ng/ml 1:300 5.09×1010 N25% Died
Note. BALB/c mice were vaccinated with Ebola VLPs or control SIV Gag VLPs and
challenged at 4 weeks after the last immunization. Blood samples were collected on day
4 post-challenge for determination of viremia by qRT-PCR. Mice were monitored for 21
days after challenge and the largest percentage of weight loss was presented.
ND: Not detected; NC: No change (b5%).
a The endpoint neutralizing titer is provided as the highest sera dilution that gives at
least 50% neutralization of pseudovirions (50% NT).
16 Y. Sun et al. / Virology 383 (2009) 12–21accordance with IACUC guidelines. Similarly, all six mice of the
EboVLP-10 group that were immunized with 10 μg Ebola VLPs
experienced rapid weight loss on day 4 post-challenge and
succumbed to the challenge on day 5. In contrast, all six mice of the
EboVLP-50 group that were immunized with 50 μg Ebola VLPs sur-
vived the challenge. Among these, only one mouse exhibited weight
loss of about 10% but showed no other signs of disease such as
hunched back or reduced activity. Continued monitoring showed that
this mouse started to gain weight on day 8 and regained its weight byFig. 4.Mice immunized with two high doses of Ebola VLPs are protected against lethal Ebo
Fig. 2. Four weeks after the second immunization, mice were challenged by i.p. injection
indicated days post-challenge for recording of weight changes after challenge. Mice in the E
with IACUC guidelines.day 11 after challenge. Blood samples were collected from all mice on
day 4 after challenge and the levels of serumviremiawere determined
by a quantitative RT-PCR assay (qRT-PCR) using in vitro transcribed GP
RNA segment as standards. As shown in Table 1, high levels of viremia
ranging from 1.64 to 9.17×1010 copies of Ebola viral genome equi-
valent per ml of blood were detected in all animals in the EboVLP-10
group as well as in ﬁve of six mice in the control group. In contrast,
viremia was only detected in one mouse in the EboVLP-50 group, and
the level (1.78×109) was 10-fold lower than those detected in the
other groups. Of note, this mouse was the same one that exhibited
weight loss after challenge as shown in Fig. 4 and has the lowest
antibody titer and neutralizing titer comparing to other animals in this
group as shown in Table 1. In addition, blood samples were also
collected from all survived mice on day 28 after challenge and no
viremia was detected (data not shown).
A third low-dose EBOV VLP immunization effectively boosts antibody
responses against GP and protects mice against Ebola virus challenge
As outlined in Fig. 2, the Group 4 mice (VLP-10-III) were
immunized three times with 10 μg EBOV VLPs at 4-week intervals, a
similar regimen as previously reported for mammalian cell-produced
Ebola VLPs (Warﬁeld et al., 2003). Blood samples from this group were
collected at 2 weeks after the second and third immunizations for
comparison of antibody responses. As shown in Fig. 5A, low levels of
antibody response against GP were detected in sera after the second
immunization, similar in range to the levels detected in Group 3 mice
(VLP-10-II) that received two immunizations with 10 μg Ebola VLPs as
shown in Fig. 3. However, the antibodies against GP were signiﬁcantly
boosted after the third immunization, resulting in levels that were
comparable to those in Group 2 mice (VLP-50-II) that received two
immunizations with 50 μg Ebola VLPs. Moreover, sera collected from
low-dose VLP-vaccinated mice after the third immunization exhibited
similar levels of neutralizing activity against Ebola GP-mediated virus
infection as those from high-dose VLP-vaccinated mice (Fig. 5B). At
12 weeks after the third immunization, mice in Group 4 were
challenged with 1000 pfu of mouse-adapted Ebola virus. As shown inla virus challenge. Mice were immunized by different VLP preparations as indicated in
of 1000 pfu mouse-adapted Ebola virus. Mice were monitored daily and weighed on
bo-10 group (6 mice) and the control group (5 of 6 mice) were sacriﬁced in accordance
Fig. 5. A third low-dose Ebola VLP immunization signiﬁcantly boosts the level of antibody responses against GP. (A) Analysis of antibody responses by ELISA. Mice (groups of 6) were
immunized intramuscularly with 10 μg Ebola VLPs or 50 μg SIV Gag VLPs three times at 4-week intervals. Serum samples were collected at two weeks after the second and third
immunizations, and assayed for Ebola GP-speciﬁc antibodies by ELISA using puriﬁed His-tagged GP1 as coating antigen. A standard curve was generated using puriﬁed mouse
antibodies for each mouse antibody subtype and used for calculation of the equivalent amount of GP-binding antibodies in serum samples. 2o, antibody responses after two
immunizations with 10 μg Ebola VLPs; 3o, antibody responses after three immunizations with 10 μg Ebola VLPs. (B) Neutralization of Ebola GP pseudotyped HIV. Serum samples
collected after two immunizations with 50 μg Ebola VLPs (VLP-50-II) or three immunizations with 10 μg Ebola VLPs (VLP-10-III) were mixed with 500 pfu of Ebola GP-HIV
pseudovirions at ﬁnal dilutions of 1:100,1:300, and 1:900 as indicated. After incubation at 37 °C for 1 h, themixtures were added to JC53 cells seeded in a 96-well plate and incubated
at 37 °C for 2 days. The level of β-galactosidase activity in each well was determined by hydrolysis of the CPRG substrate by measuring the O.D. value at 590 nm as described in
Materials andmethods. A standard curvewas constructed by infecting JC53BL cells with serial dilutions of Ebola GP-HIV pseudovirions and the neutralizing activity of serum samples
is expressed as the percentage reduction of virus titers in sample wells compared to the titers in control wells without mouse sera [(virus titer in control well−virus titer in sample
well) /virus titer in control well×100%].
17Y. Sun et al. / Virology 383 (2009) 12–21Fig. 6, three mice in this group showed weight loss and one of them
died on day 6 after challenge. As presented in Table 2, viremia was
detected in the three mice that lost weight and the levels were over
100-fold lower compared to those detected in control group mice
(Group 1). These results show that a third immunization with low-
dose Ebola VLPs signiﬁcantly boosted immune responses against GP
that were able to confer an effective protection against lethal Ebola
virus challenge at 12 weeks after the ﬁnal immunization. In addition,
mice in Group 2 (VLP-50-II) that survived the ﬁrst challenge were re-
challenged in parallel. After re-challenge, two mice showed about 10%
weight loss and viremia was also detected in these mice at levels that
were 1000-fold lower compared to those detected in control mice
(Group 1). Of note, one additional mouse also showed about 10%
weight loss and died on day 4 after re-challenge. Incidentally, this is
the same animal in which viremia was detected after the ﬁrst
challenge (#6 in the VLP-50-II Group). Surprisingly, no viremia wasdetected in serum samples collected on day 4 after re-challenge from
this mouse. Thus it is also possible that the death may result from
other factors and not due to virus infection. However, the exact reason
could not be determined in this single incidence.
Discussion
VLPs arehighlyattractive for vaccinedevelopment for several -reasons:
1) they lack viral genomicmaterial and thus are non-infectious and safe for
broad application; 2) they can be administered repeatedly to vaccinated
individuals for boosting immune responses; 3) they present viral
glycoproteins in their native conformation for eliciting neutralizing
antibodies. Currently, VLP-based vaccines are under investigation for a
number of viruses including ﬁloviruses (Bertolotti-Ciarlet et al., 2003;
CrumandRivera, 2003; Li et al.,1997; Park et al., 2003; Pushko et al., 2005;
Swenson et al., 2005; Warﬁeld et al., 2003; Yao et al., 2003). Of speciﬁc
Table 2
Viremia level, weight loss, and survival rate after lethal Ebola virus challenge (II)




VLP-10-III 1 25735 ng/ml 1:8100 ND NC Survived
2 11929 ng/ml 1:2700 ND NC Survived
3 4535 ng/ml 1:900 3.33×107 17% Survived
4 3223 ng/ml 1:900 2.51×107 15% Died
5 9370 ng/ml 1:2700 ND NC Survived
6 7823 ng/ml 1:2700 5.09×107 10% Survived
VLP-50-II
(re-challenge)
1 10822 ng/ml 1:900 ND NC Survived
2 13070 ng/ml 1:2700 3.7×106 10% Survived
3 22033 ng/ml 1:8100 ND NC Survived
4 16668 ng/ml 1:2700 5.2×106 12% Survived
5 16743 ng/ml 1:2700 ND NC Survived
6 9959 ng/ml 1:900 ND 10% Died
Note. BALB/c mice were vaccinated Ebola VLPs and challenged at 12 weeks after the
third immunization (VLP-10-III) or re-challenged at 12 weeks after the ﬁrst challenge
(VLP-50-II). Blood samples were collected on day 4 post-challenge for determination of
viremia by qRT-PCR. Mice were monitored for 21 days after challenge and the largest
percentage of weight loss was presented.
ND: Not detected; NC: No change (b5%).
a The endpoint neutralizing titer is provided as the highest sera dilution that gives at
least 50% neutralization of pseudovirions (50% NT).
18 Y. Sun et al. / Virology 383 (2009) 12–21interest, Ebola VLPs produced in mammalian 293T cells by DNA
transfection have been shown to potently activate dendritic cells (DCs)
and to confer effective protections against lethal Ebola virus challenge in
animal models including non-human primates (Swenson et al., 2005;
Warﬁeld et al., 2003; 2005; 2007a). However, production of Ebola VLPs in
mammalian293Tcells byDNA transfection gives lowyield and theprocess
will be difﬁcult to scale-up for manufacturing under Good Manufacturing
Practice (GMP) conditions. To address this issue, we and others have
investigated production of Ebola VLPs using the recombinant baculovirus
expression system and shown that co-expression of Ebola VP40 and GP
proteins in insect cells using the baculovirus expression system led to
release of ﬁlamentous VLPs which stimulate DCs similarly to VLPs
produced in mammalian 293T cells (Warﬁeld et al., 2007b; Ye et al.,
2006). Warﬁeld et al. also showed that Ebola VLPs produced in High 5
insect cells are able to protect mice against lethal Ebola virus challenge
when given in formulationwith an adjuvant (Warﬁeld et al., 2007b). Here
we show that immunization with unadjuvanted Ebola VLPs produced in
Sf9 insect cells also induced strong protective immune responses in mice
against lethal challenge by a high dose of mouse-adapted Ebola virus. Our
results agree with and extend the ﬁndings reported by Warﬁeld et al. in
their recent study, further demonstrating that Ebola VLPs produced in
insect cells are highly efﬁcacious for protection against Ebola virus
infection.
While the immune correlates for protection against Ebola virus
infection have not been deﬁned, current data from animal studies
indicates that the Ebola glycoprotein GP is the primary target for
inducing protective immune responses (Bukreyev et al., 2007; Jones
et al., 2005; Sullivan et al., 2006; Swenson et al., 2005). In this study,
we observed that two immunizations with a higher dose induced
strong antibody responses against the GP and protected mice against
lethal Ebola virus challenge whereas two immunizations with a lower
dose induced signiﬁcantly lower levels of antibody responses against
GP and no protection against lethal Ebola virus challenge was
observed. Further, mice immunized with a high dose of SIV GagFig. 6.Mice immunized with three low doses of Ebola VLPs are protected against lethal
Ebola virus challenge. Mice were immunized three times at 4-week intervals by 10 μg
Ebola VLPs. Twelve weeks after the third immunization, mice were challenged by i.p.
injection of 1000 pfu mouse-adapted Ebola virus. In addition, the 6 mice of group
EboVLP-50 that survived the ﬁrst challenge were re-challenged at the same time. Mice
were monitored daily and weighed on indicated days post-challenge for recording of
weight changes after challenge. Mice that exhibit substantial weight loss and signs of
severe disease were sacriﬁced in accordance with IACUC guidelines.VLPs that were similarly produced in insect cells did not induce
detectable antibody response against the GP and these mice all a
succumbed to challenge by Ebola virus. These results indicate that
effective protection requires induction of speciﬁc immune responses
against GP and correlate with the level of antibody responses to GP.
This is in agreement with results reported by Sullivan et al., which
showed that monkeys immunized by a lower dose of recombinant
adenovirus expressing Ebola GP showed signiﬁcantly lower titers of
antibody response against GP and these animals were not protected
against lethal Ebola virus challenge (Sullivan et al., 2006). However, it
is possible that the antibody titers may just an indicator of the overall
level of immune responses, and that both antibody and T cell res-
ponses contribute to the protection. Future studies are needed to
determine whether passive transfer of sera from VLP-vaccinated mice
alone will be able to confer protection against Ebola challenge. On the
other hand, while protection against Ebola virus infection is likely to
be mediated by both humoral and cellular immune responses
(Warﬁeld et al., 2005), the level of GP-speciﬁc antibody responses
may serve as an useful indicator to determine whether a boosting
immunization is necessary for achieving effective protection against
Ebola virus infection. However, the criteria will need to be determined
for different vaccine formulations and immunization regimens in
evaluation of their efﬁcacy.
Because of the unpredictability of Ebola virus outbreaks and their
large endemic region, it will be cost prohibitive and logistically
difﬁcult to vaccinate the whole population at risk. However, there are
two possible applications for a potential Ebola vaccine: 1) to control
the spread of an emerging outbreak; and 2) to protect people who
are at higher risk of infection. Under the ﬁrst scenario, it will be
highly desirable for a candidate ﬁlovirus vaccine strategy to elicit
protective immune responses rapidly for mounting a quick response
to a suspected outbreak to protect people who are at immediate risk.
In this respect, several viral-vector-based Ebola vaccines hold a
potential advantage as they have been shown to induce protective
immune responses by a single immunization despite their perceived
limitations in overcoming pre-existing immunity against viral vectors
or safety concerns (Bukreyev et al., 2007; Jones et al., 2005; Sullivan
et al., 2006). In contrast, while it has been shown that adjuvanted
Ebola VLPs were able to protect guinea pigs against lethal Ebola
challenge by a single immunization (Swenson et al., 2005), protection
of non-human primates against lethal Ebola virus challenge was only
shown by three immunizations with adjuvanted Ebola VLPs (War-
ﬁeld et al., 2007a). Nonetheless, it is encouraging to note that the
19Y. Sun et al. / Virology 383 (2009) 12–21antibody responses induced after two immunizations reached similar
levels as those detected after three immunizations in non-human
primates (Warﬁeld et al., 2007a). Our results show that immuniza-
tion with a higher dose of unadjuvanted Ebola VLPs can induce
strong immune responses against Ebola GP and confer complete
protection against lethal Ebola virus challenge by two immuniza-
tions. Further investigations are needed to optimize the VLP vaccine
dose, its formulation with an adjuvant, as well as the immunization
regimen for achieving rapid protection against Ebola virus infection
in non-human primates. Under the second scenario, it will require an
Ebola vaccine strategy that can provide long-term protection for
people who may be at constant risk of infection, such as researchers
working with these highly dangerous viruses, health care providers
working in endemic areas, as well as personnel to be deployed in
such regions. We observed in this study that the sub-optimal
immune responses induced by two immunizations with a lower
dose of Ebola VLPs do not seem to beneﬁt vaccinated animals against
lethal Ebola virus challenge at all, with no reduction in serum viremia
levels and no delay in time to death after challenge. Therefore, it will
likely be necessary to give boosting immunizations for maintaining
the levels of protective immune responses against Ebola virus
infection. On the other hand, our results also demonstrate that the
sub-optimal immune responses could be effectively boosted by an
additional vaccination with Ebola VLPs which resulted in effective
protection against lethal challenge by a high dose of Ebola virus.
Thus, in the second scenario, Ebola VLP vaccines, which can be
administered repeatedly to boost the levels of immune responses,
will likely to be more advantageous compared to viral vector-based
vaccines, which also induce immune responses against the vector
that may limit their efﬁcacy in boosting immunizations. It is also
noted that the protective efﬁcacy in the second challenge study, in
which challenge was given at 12 weeks after the immunizations,
seems to be less effective (as shown in Table 2). Similar results were
also obtained with the re-challenged group. It is possible that
immune responses at this later time point may become lower over
time and need to be re-activated to control virus replication. This
observation further underscores the need to give boosting immuni-
zations for maintaining the levels of protective immune responses
against Ebola virus infection.
In summary, Ebola VLPs produced in insect cells are able to induce
strong antibody responses against Ebola GP that effectively neutralize
GP-mediated virus infection. The immune responses induced by
immunization with insect cell-derived Ebola VLPs are highly
efﬁcacious for protection against infection by Ebola virus. Further,
when given in formulation with an adjuvant, Ebola VLP vaccine dose
can be signiﬁcantly reduced and still confer effective protection
against lethal Ebola virus challenge (Warﬁeld et al., 2007b). Given the
high yield for production of VLPs in insect cells using the
recombinant baculovirus expression system and the ease to scale-
up the process for manufacturing under GMP conditions, the insect
cell-produced Ebola VLPs represent an attractive and cost-effective
approach for the development of an effective vaccine strategy against
Ebola virus infection. Of note, the Ebola VLPs in current form are far
from optimal. In characterization of Ebola VLPs, we found that the GP
constitutes roughly 2% of the total protein in VLP preparations. While
it is possible that the antibodies used in the quantitative ELISA
analysis may be more reactive to puriﬁed GP that was prepared in
mammalian cells and thus resulting in a lower estimation of the
amount of GP in VLPs that were produced in insect cells, these results
also indicate that the process for Ebola VLP production may be
further optimized. Thus, additional studies on Ebola VLP assembly
and release from insect cells are needed to improve the level of GP
incorporation in VLPs that may enhance their immunogenicity.
Moreover, VLPs are also highly versatile for manipulation during
production to incorporate immune-stimulatory molecules (Guo et al.,
2003, Sailaja et al., 2007; Skountzou et al., 2007), and similarstrategies may also be applied to the design of Ebola VLP vaccines to
augment induction of protective immune responses against Ebola
virus infection. Future studies to optimize Ebola VLP design and
formulation will lead to development of more potent VLP-based
vaccines that may rapidly induce protective immune responses as
shown by recombinant viral vector-based vaccines.
Materials and methods
Cells and antibodies
Spodoptera frugiperda Sf9 insect cells were cultured in SF-900 II
serum-free medium with penicillin/streptomycin in suspension.
Monoclonal antibodies against Ebola VP40 and GP proteins were
kindly provided by Dr. Y. Kawaoka (Univ. Wisconsin, Madison.).
Polyclonal anti-serum against Ebola virus was kindly provided by Dr P.
Rollin (CDC).
Virus and biosafety
The mouse-adapted Ebola virus Zaire strain was obtained from
USAMRIID, which was originally obtained by Bray et al. through
passage in suckling balb/c mouse (Bray et al., 1998). Mouse-adapted
Ebola Zaire stock was propagated in Vero E6 cells. The ﬂasks were
infected at an MOI of 0.01. On day seven post-infection, the virus was
harvested and the infectious titer was determined by a plaque assay.
All experiments involving infectious Ebola virus were performed at
the maximum containment facility at the Southwest Foundation for
Biomedical Research, San Antonio, Texas.
Production and characterization of Ebola VLPs
Generation of recombinant baculoviruses expressing Ebola VP40
(rBV-VP40) or GP (rBV-GP) proteins has been described previously
(Ye et al., 2006). For VLP production, Sf9 cells (2×106/ml) were co-
infected with rBV-VP40 and rBV-GP at MOIs (multiplicity of
infection) of 2 and 5 respectively, and VLPs released into the
medium were collected at 60 h post-infection. After clariﬁcation of
cell debris, VLPs were concentrated by ultra-centrifugation and
further puriﬁed through a discontinuous sucrose gradient (10–50%).
Puriﬁed VLPs were then concentrated by ultra-centrifugation and re-
suspended in PBS. Protein concentrations of VLPs as well as puriﬁed
Ebola GP were determined using a Bradford assay kit as well as a
BCA assay kit, which gave similar results in this study. The VLP
preparations were adjusted with PBS, giving a ﬁnal protein
concentration of 1 μg/μl.
Puriﬁed VLPs were characterized by Coomassie blue as well as
Western blot analysis for the presence of EBOV VP40 and GP proteins,
and examined by electron microscopy under a Hitachi-H7500 trans-
mission electron microscope by negative staining with 1% uranyl
acetate, following established protocols described previously (Ye et al.,
2006). The amount of Ebola GP incorporated in Ebola VLPs was
determined by a quantitative Elisa. Brieﬂy, 96-well plates were coated
with an anti-GP monoclonal antibody overnight at 4 °C followed by
wash and blocking with PBS-T (PBS plus 0.5% Tween-20) plus 2% BSA,
and then addition of serial dilutions of VLPs in triplicates for 2 h at
room temperature. The plates were washed again and then incubated
with rabbit antibodies against Ebola virus for 2 h at room temperature,
followed by addition of HPR-conjugated goat-anti-rabbit secondary
antibodies and then development of color with TMB (Sigma). A
standard curve was obtained by using known amounts of puriﬁed
Ebola GP1-histag proteins, which were produced in HeLa cells using
the recombinant vaccinia virus expression system as described
previously (Ye et al., 2006), to determine the amount of Ebola GP
in Ebola VLPs. After characterization, VLPs were stored in aliquots
at −80 °C until use.
20 Y. Sun et al. / Virology 383 (2009) 12–21Immunization of mice, sample collection, and challenge
Female BALB/c mice (6–8 weeks old) were purchased from Charles
River Laboratory and housed at the Emory University Animal Facility
or the SFBR Animal Facility. All animal studies were carried out
following approved IACUC protocols. Immunization of mice was
carried out by intramuscular injection of VLP vaccines at both sides
quadriceps at 4-week intervals using doses as indicated for each
group. Blood samples were collected from the retro-orbital sinus
under anesthesia at 2 weeks after each immunization, and stored at
−80 °C until further analysis.
Lethal EBOV challenge studies were carried out in the BSL-4 animal
facility at SFBR. After the ﬁnal immunization, mice were challenged by
intra peritoneal injection with 1000 pfu of mouse-adapted EBOV
diluted in PBS. After challenge, mice were monitored daily for weight
changes and signs of disease. Blood was collected on day 4 post-
challenge for determination of viremia.
Isolation of total RNA and qRT-PCR
Total RNA from mouse blood was isolated using the Mouse
RiboPure-Blood RNA isolation kit (Ambion) according to the manufac-
turer's recommendations and used in a qRT-PCR assay. The qRT-PCR
was performed using RNA UltraSense one-step qRT-PCR system
(Invitrogen) using Ebola Zaire speciﬁc primers and Probe (forward
primer: 5′-ACTGATCACAGGCGGGAGAA-3′; Probe: FAM-5′-AATTGTC-
AATGCTCAACCCAAATGC-3′-TAMRA; reverse primer: 5′-GCTGG-
CCCGAAATATGGTATC-3′). Reactions (20 μl) contained reaction buffer,
E-mix, BSA, 0.25 μM of each primer, 0.25 μM TaqMan probe, and total
RNA from mouse samples. Ampliﬁcations were performed using a
LightCycler 1.5 instrument (Roche) set at the default thermal proﬁle
(RT reaction at 45 °C for 30min, Platinum Taq polymerase activation at
95 °C for 2 min, 45 cycles of denaturation at 95 °C for 15 s and
annealing/extension at 60 °C for 30 s). Ebola Zaire GP RNA copy
numbers (expressed as copies per ml of blood) in blood samples were
quantiﬁed by extrapolating from the standard curve plot of Ct values
generated similarly using reactions containing T7 in vitro transcribed
Ebola Zaire GP RNA transcript prepared as 10-fold RNA dilution series.
ELISA
Ebola GP-speciﬁc antibodies were measured in individual mouse
serum samples by an enzyme-linked immunoabsorbent assay
(ELISA) using puriﬁed His-tagged GP1 proteins as coating antigens.
Brieﬂy, the assays were performed in 96-well polystyrene microtiter
plates (Nunc) coated overnight at 4 °C with puriﬁed His-tagged GP1
and VP40 respectively at a concentration of 2 μg/ml. Serial dilutions
of serum samples were incubated at RT for 2 h on coated and
blocked ELISA plates, and the bound immunoglobulins were detected
with HRP-conjugated goat against mouse IgG, IgG1, IgG2a, or IgG 2b
secondary antibodies (Southern Biotechnology Associates). The wells
were developed with 3,3′,5,5′-Tetramethylbenzidine (TMB) (Sigma).
The color reaction was stopped with hydrochloric acid (0.2 N) and
the absorbance at 450 nm was read in an EL312 Bio-Kinetics
microplate reader (Bio-Tek Instruments Inc., Winooski, VT). A
standard curve was constructed by coating each ELISA plate with
serial 2-fold dilutions of puriﬁed mouse IgG, IgG1, IgG2a, or IgG2b
with known concentrations respectively, and the concentrations of
Ebola GP-speciﬁc antibodies in serum samples were calculated using
obtained standard curves and expressed as the amount of antigen-
speciﬁc antibody per ml of serum sample (ng/ml).
Detection of neutralizing activity against EBOV GP-pseudovirus
Neutralizing antibodies against Ebola GP were analyzed using a
single-round infectivity assay as used in our previous studies (Ye et al.,2006) with slight modiﬁcations. Brieﬂy, Ebola GP pseudotyped HIV
was prepared by cotransfection of 293T cells with DNA vectors for the
HIV backbone and the Ebola GP and the titer of released pseudovirions
was determined in the JC53BL cells by staining for β-galactosidase
expressing cells. For analysis of neutralizing antibodies, serial 3-fold
dilutions of heat-inactivated serum samples were incubated with
500 pfu of Ebola GP-HIV pseudovirions for 1 h at 37 °C, and then added
to JC53BL cells seeded in a 96-well plate in the presence of DEAE-
dextran. The JC53BL cells in controlwells were infectedwith 500 pfu of
Ebola GP-HIV pseudovirions in the absence of mouse sera. After
incubation at 37 °C for 2 days, 5 μl of 20%Nonidet P-40 (V/V)was added
to eachwell to lyse the cells, and the level of β-galactosidase activity in
eachwellwas determined as described previously (Yang and Compans,
1997). Brieﬂy, 50 μl of cell lysate from each well with 50 μl of CPRG
(chlorophenol red-3-D-galactopyranoside) substrate solution (16 mM
CPRG, 0.12 M Na2HP04, 0.08 M NaH2PO4, 0.02 M KCI, 0.002 M MgSO4,
0.01 M β-mercaptoethanol) for 30 min at room temperature followed
bymeasuring theO.D. value at 590nmwith anELISA reader. A standard
curvewas constructed by infecting JC53BL cells with serial dilutions of
Ebola GP-HIV pseudovirions for calculation of virus titers in each
sample well. Neutralizing activity is expressed as the percentage
reduction of virus titers in sample wells compared to the titers in
control wells without mouse sera [(virus titer in control well−virus
titer in sample well) /virus titer in control well×100%]. The endpoint
neutralizing titer is provided as the highest sera dilution that gives at
least 50% neutralization of pseudovirions (50% NT).
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